HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients
BackgroundOverexpression of human epidermal growth factor receptor type 2 (HER2) occurs in almost 25-30% of androgen receptor (AR)-positive salivary gland carcinomas (SGCs), notably salivary duct carcinoma (SDC) and adenocarcinoma not otherwise specified (NOS). In the last years, several studies hav...
Main Authors: | Stefano Cavalieri, Imperia Nuzzolese, Arianna Ottini, Cristiana Bergamini, Carlo Resteghini, Elena Colombo, Salvatore Alfieri, Pasquale Quattrone, Giuseppina Calareso, Nicola Alessandro Iacovelli, Marzia Franceschini, Lisa Licitra |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1096068/full |
Similar Items
-
Management of patients with skin adnexal carcinomas
by: Stefano Cavalieri, et al.
Published: (2023-01-01) -
NUT carcinoma of the submandibular gland: A case report
by: Simone Rota, et al.
Published: (2023-12-01) -
Editorial: Diagnosis, epidemiology and treatment of salivary gland carcinomas
by: Imperia Nuzzolese, et al.
Published: (2024-02-01) -
First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study
by: Paul V. Viscuse, et al.
Published: (2019-08-01) -
Multidisciplinary management of pregnancy-associated and early post-partum head and neck cancer patients
by: Cristiana Bergamini, et al.
Published: (2023-11-01)